CD274 and non-small cell lung carcinoma: For instance, in NSCLC cell lines, 5-azacytidine treatment upregulates the JAK/STAT pathway stimulating the expression of genes involved in antigen presentation and increasing expression of PD-L1, a key ligand-mediator of immune tolerance [27, 32].